A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer
Clinical trial NCT04562298 · TERMINATED
Trial details
- NCT number
- NCT04562298
- Sponsor
- Shanghai East Hospital
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-21
- Primary completion
- 2022-06-07
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.